Logotype for Ingevity Corporation

Ingevity (NGVT) Q3 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Ingevity Corporation

Q3 2024 earnings summary

17 Jan, 2026

Executive summary

  • Q3 2024 net sales were $376.9 million, down 16% year-over-year, mainly due to Performance Chemicals repositioning, lower industrial demand, and weather-related impacts.

  • Net loss for Q3 2024 was $107.2 million, driven by $86.9 million in restructuring charges, a $100 million CTO contract termination, and a $349.1 million goodwill impairment in Performance Chemicals.

  • Adjusted EBITDA was $106.4 million (28.2% margin), down 3.6% year-over-year, with gross margin up 610 basis points due to a shift toward higher-margin businesses.

  • Performance Materials and Advanced Polymer Technologies segments delivered sales growth and margin improvements, while Performance Chemicals saw significant repositioning and operational declines.

  • Major restructuring included plant closures, workforce reductions, and exit from lower-margin markets, with $18 million in Q3 savings and $65–$75 million in 2024 savings expected.

Financial highlights

  • Free cash flow was $28.5 million, including a $50 million CTO contract termination payment and $21 million in restructuring charges.

  • Net leverage ratio was 4.0x, with expectations to reach 3.5x by year-end; bank-calculated leverage at 3.0x.

  • Adjusted diluted EPS was $1.10, down 9.1% year-over-year; basic and diluted EPS for Q3 2024 was $(2.95).

  • Cash and cash equivalents at quarter-end were $135.5 million.

  • Capital expenditures for nine months were $52.7 million; full-year projected at $90–$100 million.

Outlook and guidance

  • Full-year 2024 sales expected at the lower end of $1.40–$1.50 billion, with Adjusted EBITDA between $350–$360 million.

  • Performance Chemicals repositioning expected to yield $95–$110 million in annualized cash savings, with $65–$75 million realized in 2024.

  • Priorities include improved execution, leverage reduction, and a portfolio review, with a target of $400 million EBITDA and leverage around 3x by year-end 2025.

  • Free cash flow expected to remain positive despite contract termination payments.

  • Key uncertainties include global industrial recovery, geopolitical risks, U.S. election dynamics, and auto production pace.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more